Literature DB >> 19475619

Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Mary K Grabowski1, Raphael P Viscidi, Joseph B Margolick, Lisa P Jacobson, Keerti V Shah.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe neurological disorder due to JC virus (JCV) infection. Pre-diagnostic biological markers and risk factors for PML are not well understood. We conducted a case-control study nested within the Multicenter AIDS Cohort Study to examine the association between JCV viruria and viremia and serum antibody to JCV capsids, in relation to subsequent PML diagnoses, 5 months to 12 years later. Other demographic and immunologic factors were also examined. The study population included 28 incident cases of PML, 26 matched HIV-positive controls, and 50 HIV-negative controls. Prevalence of JCV viruria was 37% in cases, 42% in HIV-positive controls, and 28% in HIV-negative controls (P = 0.43). Among persons with JCV viruria, persistent viruria was more common in cases (89%) than in HIV-positive controls (33%) (P = 0.02). Presence of JCV viruria was not related to the time to PML diagnosis (OR: 1.03, 95% CI: 0.8-1.4); however, the urinary concentration of JCV DNA increased with proximity to the date of PML diagnosis in cases. JCV seropositivity did not differ between cases or controls (P = 0.42). Four cases tested JCV seronegative, including one case only 5 months prior to diagnosis with PML. JCV DNA was detected in the serum of one HIV-positive control. Smoking was the only demographic variable analyzed associated with an increased risk for PML (MOR: 9.0, 95% CI: 1.2-394.5). The results suggest that persistent JCV viruria and increasing urinary concentration of JCV DNA may be predictive of PML for some patients. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475619      PMCID: PMC2969173          DOI: 10.1002/jmv.21493

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  47 in total

1.  Cellular and humoral immune response in progressive multifocal leukoencephalopathy.

Authors:  F Weber; C Goldmann; M Krämer; F J Kaup; M Pickhardt; P Young; H Petry; T Weber; W Lüke
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

Review 2.  Progressive multifocal leukoencephalopathy.

Authors:  J R Berger; E O Major
Journal:  Semin Neurol       Date:  1999       Impact factor: 3.420

3.  Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus.

Authors:  R S Hamilton; M Gravell; E O Major
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays.

Authors:  Raphael P Viscidi; Dana E M Rollison; Emma Viscidi; Barbara Clayman; Elizabeth Rubalcaba; Richard Daniel; Eugene O Major; Keerti V Shah
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

5.  Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers.

Authors:  W A Knowles; D Pillay; M A Johnson; J F Hand; D W Brown
Journal:  J Med Virol       Date:  1999-12       Impact factor: 2.327

Review 6.  Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions.

Authors:  Joseph R Berger
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

7.  Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.

Authors:  Brynjar Vidarsson; Deane F Mosher; M Shahriar Salamat; Helgi J Isaksson; Pall T Onundarson
Journal:  Am J Hematol       Date:  2002-05       Impact factor: 10.047

8.  Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  John A Lednicky; Regis A Vilchez; Wendy A Keitel; Fehmida Visnegarwala; Zoe S White; Claudia A Kozinetz; Dorothy E Lewis; Janet S Butel
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

9.  Lack of serological evidence for an association between simian virus 40 and lymphoma.

Authors:  Silvia de Sanjose; Keerti V Shah; Eva Domingo-Domenech; Eric A Engels; Alberto Fernandez de Sevilla; Tomas Alvaro; Mercedes Garcia-Villanueva; Vicens Romagosa; Eva Gonzalez-Barca; Raphael P Viscidi
Journal:  Int J Cancer       Date:  2003-04-20       Impact factor: 7.396

10.  The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study.

Authors:  Paul D Ling; John A Lednicky; Wendy A Keitel; David G Poston; Zoe S White; RongSheng Peng; Zhensheng Liu; Satish K Mehta; Duane L Pierson; Cliona M Rooney; Regis A Vilchez; E O'Brian Smith; Janet S Butel
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

View more
  4 in total

1.  JC virus identified in a patient with persistent and severe West Nile virus disease.

Authors:  Neta S Zuckerman; Victoria Indenbaum; Ron Milo; Ella Mendelson; Yaniv Lustig
Journal:  J Neurovirol       Date:  2019-04-04       Impact factor: 2.643

2.  JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.

Authors:  Raphael P Viscidi; Nina Khanna; Chen S Tan; Xiuhung Li; Lisa Jacobson; David B Clifford; Avindra Nath; Joseph B Margolick; Keerti V Shah; Hans H Hirsch; Igor J Koralnik
Journal:  Clin Infect Dis       Date:  2011-08-18       Impact factor: 9.079

3.  Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.

Authors:  Caroline F Ryschkewitsch; Peter N Jensen; Eugene O Major
Journal:  J Clin Virol       Date:  2013-04-23       Impact factor: 3.168

4.  JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.

Authors:  Roberta Lanzillo; Raffaele Liuzzi; Luca Vallefuoco; Marcello Moccia; Luca Amato; Giovanni Vacca; Veria Vacchiano; Giuseppe Portella; Vincenzo Brescia Morra
Journal:  Ther Clin Risk Manag       Date:  2014-10-09       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.